- Yu H, Wang M, Chang H et al.Prevalence of antibodies against enterovirus 71 in children from Lu’an City in Central China. Jpn J Infect Dis2011;64: 528–532.
- Toya M, Endo Y, Tanizaki H, Fujisawa A, Tanioka M, Miyachi Y.An adult case of severe hand-foot-mouth disease accompanying persistent fever and systemic arthritis. Dermatol Online J2012;18: 14.
- Hamaguchi T, Fujisawa H, Sakai K et al.Acute encephalitis caused by intrafamilial transmission of enterovirus 71 in adult. Emerg Infect Dis2008;14: 828–830.
- Yang F, Ren L, Xiong Z et al.Enterovirus 71 outbreak in the People’s Republic of China in 2008. J Clin Microbiol2009;47: 2351–2352.
- De W, Changwen K, Wei L et al.A large outbreak of hand, foot, and mouth disease caused by EV71 and CAV16 in Guangdong, China, 2009. Arch Virol2011;156: 945–953.
- Ji H, Li L, Liu Y et al.Seroepidemiology of human enterovirus 71 and coxsackievirusA16 in Jiangsu province, China. Virol J2012;9: 248.
- Rabenau HF, Richter M, Doerr HW.Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. Med Microbiol Immunol2010;199: 45–51.
- Chen X, Wang C, Xu L et al.A laboratory evaluation of medicinal herbs used in china for the treatment of hand, foot, and mouth disease. Evid Based Complement Alternat Med: eCAM2013;2013: 504563.
- Zeng M, El Khatib NF, Tu S et al.Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai. J Clin Virol2012;53: 285–289.
- Zhu FC, Liang ZL, Meng FY et al.Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants. PloS ONE2012;7: e37206.
- Luo ST, Chiang PS, Chao AS et al.Enterovirus 71 maternal antibodies in infants, Taiwan. Emerg Infect Dis2009;15: 581–584.
- Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE.Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis2003;9: 78–85.
- Ruohola A, Waris M, Allander T, Ziegler T, Heikkinen T, Ruuskanen O.Viral etiology of common cold in children, Finland. Emerg Infect Dis2009;15: 344–346.
- Cardosa MJ, Krishnan S, Tio PH, Perera D, Wong SC.Isolation of subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and mouth disease in Sibu, Sarawak. Lancet1999;354: 987–991.
- Catanzaro AT, Koup RA, Roederer M et al.Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis2006;194: 1638–1649.
- McElrath MJ, de Rosa SC, Moodie Z et al.HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet2008;372: 1894–1905.
- Xiang Z, Gao G, Reyes-Sandoval A et al.Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol2002;76: 2667–2675.
- Xiang Z, Li Y, Cun A et al.Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis2006;12: 1596–1599.
- Shi J, Huang X, Liu Q, Huang Z.Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine2013;31: 2130–2136.
- Ku Z, Ye X, Huang X et al.Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PloS ONE2013;8: e57601.
- Sprangers MC, Lakhai W, Koudstaal W et al.Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol2003;41: 5046–5052.
- Zhang S, Huang W, Zhou X, Zhao Q, Wang Q, Jia B.Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J Med Virol2013;85: 1077–1084.
- Davenport CB.Analysis of variance applied to human genetics. Proc Natl Acad Sci USA1940;1: 1–3.
- Spearman C.The proof and measurement of association between two things. Int J Epidemiol2010;5: 1137–1150.
- Diedrich S, Weinbrecht A, Schreier E.Seroprevalence and molecular epidemiology of enterovirus 71 in Germany. Arch Virol2009;154: 1139–1142.
- Zhu Z, Zhu S, Guo X et al.Retrospective seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 circulated wildly in central and southern China before large-scale outbreaks from 2008. Virol J2010;7: 300.
- Chang LY, Hsiung CA, Lu CY et al.Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res2006;60: 466–471.
- Yang C, Deng C, Wan J, Zhu L, Leng Q.Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications. Virol J2011;8: 306.
- Fox JP, Hall CE, Cooney MK.The Seattle Virus Watch. VII. Observations of adenovirus infections. Am J Epidemiol1977;105: 362–386.
- Thorner AR, Vogels R, Kaspers J et al.Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol2006;44: 3781–3783.
- Kostense S, Koudstaal W, Sprangers M et al.Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS2004;18: 1213–1216.
- Mast TC, Kierstead L, Gupta SB et al.International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine2010;28: 950–957.
- Nwanegbo E, Vardas E, Gao W et al.Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol2004;11: 351–357.
- Sumida SM, Truitt DM, Lemckert AA et al.Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol2005;174: 7179–7185.
- Pilankatta R, Chawla T, Khanna N, Swaminathan S.The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines. J Med Virol2010;82: 407–414.
- Abbink P, Lemckert AA, Ewald BA et al.Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol2007;81: 4654–4663.
- Dudareva M, Andrews L, Gilbert SC et al.Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine2009;27: 3501–3504.
- Yu B, Zhou Y, Wu H et al.Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China. J Med Virol2012;84: 1408–1414.
- Sun C, Zhang Y, Feng L et al.Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. Vaccine2011;29: 3837–3841.
- Roy S, Kobinger GP, Lin J et al.Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine2007;25: 6845–6851.
- Kobinger GP, Figueredo JM, Rowe T et al.Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. Vaccine2007;25: 5220–5231.
- Kobinger GP, Feldmann H, Zhi Y et al.Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology2006;346: 394–401.
- Choose new content alerts to be informed about new research of interest to you
- Easy remote access to your institution's subscriptions on any device, from any location
- Save your searches and schedule alerts to send you new results
- Export your search results into a .csv file to support your research